US biotech company Graviton Bioscience announced on Thursday a strategic investment by French pharmaceutical giant Sanofi.Under the terms of the agreement, Sanofi will receive a right of first.
/PRNewswire/ Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil.
The Paris Bourse ended the session down 0.89%, at 7588 points, penalized by the -10.3% plunge in Dassault Systèmes, the -9.2% fall in BNP-Paribas and the -4.1% fall in Sanofi. Last night, as.